| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Maria Constanza Paz, Maria Amparo Assis, Ricardo J Cabrera, Liliana M Cancela, Claudia Bregonzi. The AT₁ angiotensin II receptor blockade attenuates the development of amphetamine-induced behavioral sensitization in a two-injection protocol. Synapse (New York, N.Y.). vol 65. issue 6. 2012-03-12. PMID:20936684. |
angiotensin (ang) ii receptors are found on the soma and terminals of mesolimbic dopaminergic neurons and it has been shown that ang ii acting through its at₁ receptors facilitates dopamine release. |
2012-03-12 |
2023-08-12 |
rat |
| Hideaki Kabuto, Tomoko T Yamanush. Effects of zingerone [4-(4-hydroxy-3-methoxyphenyl)-2-butanone] and eugenol [2-methoxy-4-(2-propenyl)phenol] on the pathological progress in the 6-hydroxydopamine-induced Parkinson's disease mouse model. Neurochemical research. vol 36. issue 12. 2012-03-12. PMID:21769642. |
parkinson's disease (pd) is characterized by progressive degeneration of dopaminergic neurons in the nigrostriatal system and dopamine (da) depletion in the striatum. |
2012-03-12 |
2023-08-12 |
mouse |
| Masako Yamazaki, Jun Tomita, Kazuhiro Takahama, Taro Ueno, Madoka Mitsuyoshi, Erina Sakamoto, Shoen Kume, Kazuhiko Kum. High calorie diet augments age-associated sleep impairment in Drosophila. Biochemical and biophysical research communications. vol 417. issue 2. 2012-03-12. PMID:22197809. |
these changes are more evident in the dopamine transporter mutant, fumin, that displays a short sleep phenotype due to enhanced dopaminergic signaling. |
2012-03-12 |
2023-08-12 |
drosophila_melanogaster |
| M D Gottwal. Maximizing the benefit:risk ratio of levodopa therapy in Parkinson's disease. Pharmacotherapy. vol 19. issue 11 Pt 2. 2012-03-09. PMID:10555944. |
strategies for providing continuous dopaminergic replacement include administration of levodopa by continuous infusion, controlled-release levodopa, long-acting dopamine agonists, and inhibitors of levodopa metabolism. |
2012-03-09 |
2023-08-12 |
Not clear |
| M S Lue. Interventions to achieve tonic exposure to levodopa: delaying or preventing the onset of motor complications. Pharmacotherapy. vol 19. issue 11 Pt 2. 2012-03-09. PMID:10555945. |
long-term exposure to the oscillations in levodopa-derived dopamine also is suggested to cause postsynaptic changes within the dopaminergic system, leading to further reductions in the drug's efficacy. |
2012-03-09 |
2023-08-12 |
Not clear |
| Mohammad-Reza Zarrindast, Ailar Sroushi, Maryam Bananej, Nasim Vousooghi, Shokouh Hamidkhanih. Involvement of the dopaminergic receptors of the rat basolateral amygdala in anxiolytic-like effects of the cholinergic system. European journal of pharmacology. vol 672. issue 1-3. 2012-03-07. PMID:21968140. |
furthermore, dopaminergic system activation probably via dopamine d(1) and d(2) receptors is necessary for mediating anxiolytic-like effects of physostigmine. |
2012-03-07 |
2023-08-12 |
rat |
| Sarah Hohmann, Nina Schweinfurth, Thorsten Lau, Michael Deuschle, Florian Lederbogen, Tobias Banaschewski, Patrick Schlos. Differential expression of neuronal dopamine and serotonin transporters DAT and SERT in megakaryocytes and platelets generated from human MEG-01 megakaryoblasts. Cell and tissue research. vol 346. issue 2. 2012-03-06. PMID:22006250. |
in the central nervous system, serotonergic and dopaminergic signaling is terminated by the activity of specialized transporter proteins for serotonin (sert) and dopamine (dat). |
2012-03-06 |
2023-08-12 |
human |
| Dimitrios Kapogiannis, Eric Mooshagian, Paul Campion, Jordan Grafman, Trelawny J Zimmermann, Kelsey C Ladt, Eric M Wasserman. Reward processing abnormalities in Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society. vol 26. issue 8. 2012-02-29. PMID:21538525. |
we examined the role of dopamine in this phenomenon by testing 13 mildly affected patients with parkinson's disease, off and on dopaminergic medications, and 13 healthy, age-matched controls. |
2012-02-29 |
2023-08-12 |
Not clear |
| A R Burke, M J Watt, G L Forste. Adolescent social defeat increases adult amphetamine conditioned place preference and alters D2 dopamine receptor expression. Neuroscience. vol 197. 2012-02-27. PMID:21933700. |
components of the brain's dopaminergic system, such as dopamine receptors, undergo final maturation in adolescence. |
2012-02-27 |
2023-08-12 |
human |
| Marise W J Machielsen, Lieuwe de Haa. Differences in efficacy on substance abuse between risperidone and clozapine supports the importance of differential modulation of dopaminergic neurotransmission. Psychopharmacology bulletin. vol 42. issue 4. 2012-02-23. PMID:20581792. |
substance abuse is associated with changes in dopaminergic neurotransmission of dopamine d1 and d2 receptors. |
2012-02-23 |
2023-08-12 |
Not clear |
| Ma Rosario Luquin-Piudo, Pilar San. Dopamine receptors, motor responses, and dopaminergic agonists. The neurologist. vol 17. issue 6 Suppl 1. 2012-02-21. PMID:22045321. |
dopamine receptors, motor responses, and dopaminergic agonists. |
2012-02-21 |
2023-08-12 |
Not clear |
| Jeff A Beele. Preservation of function in Parkinson's disease: what's learning got to do with it? Brain research. vol 1423. 2012-02-17. PMID:22000081. |
the 'integrative selective gain' framework proposed here integrates dopaminergic mechanisms known to modulate basal ganglia throughput into a single conceptual framework: (1) synaptic weights, the neural instantiation of accumulated experience and skill modulated by dopamine-dependent plasticity and (2) system gain, the operating parameters of the basal ganglia, modulated by dopamine's on-line effects on cell excitability, glutamatergic transmission and the balance between facilitatory and inhibitory pathways. |
2012-02-17 |
2023-08-12 |
Not clear |
| Heramb Chadchankar, Leonid Yavic. Sub-regional differences and mechanisms of the short-term plasticity of dopamine overflow in striatum in mice lacking alpha-synuclein. Brain research. vol 1423. 2012-02-17. PMID:22000591. |
mice lacking the pre-synaptic protein alpha-synuclein (α-syn) demonstrate enhanced facilitation of dopamine (da) overflow in dorsal striatum following repeated, high-frequency burst stimulation of the dopaminergic pathways. |
2012-02-17 |
2023-08-12 |
mouse |
| Gregory C Hadlock, Chad C Nelson, Anthony J Baucum, Glen R Hanson, Annette E Fleckenstei. Ex vivo identification of protein-protein interactions involving the dopamine transporter. Journal of neuroscience methods. vol 196. issue 2. 2012-02-16. PMID:21291912. |
the dopamine (da) transporter (dat) is a key regulator of dopaminergic signaling as it mediates the reuptake of extrasynaptic da and thereby terminates dopaminergic signaling. |
2012-02-16 |
2023-08-12 |
rat |
| C Villa, B Pascual-Sedano, J Pagonabarraga, J Kulisevsk. Impulse control disorders and dopaminergic treatments in Parkinson's disease. Revue neurologique. vol 167. issue 11. 2012-02-16. PMID:21596410. |
compelling evidence has stressed the relation between dopaminergic replacement and development of icds in pd, especially but not exclusively, with dopamine agonist therapy. |
2012-02-16 |
2023-08-12 |
Not clear |
| Jan Kassubek, Birgit Abler, Elmar H Pinkhard. Neural reward processing under dopamine agonists: imaging. Journal of the neurological sciences. vol 310. issue 1-2. 2012-02-16. PMID:21762926. |
impulse control disorders (icds) are increasingly reported as a considerable side-effect of treatment with dopaminergic medication (both levodopa and dopamine agonists (da)). |
2012-02-16 |
2023-08-12 |
Not clear |
| Tais S Moriyama, André C Felicio, Marcos H N Chagas, Vítor S Tardelli, Henrique Ballalai Ferraz, Vitor Tumas, Edson Amaro-Junior, Luiz Augusto F Andrade, Jose Alexandre Crippa, Rodrigo A Bressa. Increased dopamine transporter density in Parkinson's disease patients with Social Anxiety Disorder. Journal of the neurological sciences. vol 310. issue 1-2. 2012-02-16. PMID:21783205. |
the aim of this study was to investigate a possible dopaminergic mechanism involved in pd patients with sad, by correlating striatal dopamine transporter binding potential (dat-bp) with intensity of social anxiety symptoms in pd patients using spect with trodat-1 as the radiopharmaceutical. |
2012-02-16 |
2023-08-12 |
Not clear |
| Kemal Bayulkem, Grisel Lope. Clinical approach to nonmotor sensory fluctuations in Parkinson's disease. Journal of the neurological sciences. vol 310. issue 1-2. 2012-02-16. PMID:21872276. |
these include reduction of dopaminergic medication, use of long-acting dopamine agonists or controlled released levodopa (ld), surgical intervention, and/or targeted pharmacological intervention to minimize dopaminergic side effects. |
2012-02-16 |
2023-08-12 |
Not clear |
| Roberto Cilia, Thilo van Eimere. Impulse control disorders in Parkinson's disease: seeking a roadmap toward a better understanding. Brain structure & function. vol 216. issue 4. 2012-02-10. PMID:21541715. |
it is safe to say that dopaminergic drugs, particularly dopamine agonists, are able to induce icds only in a minority of patients, while the majority are somehow protected from this adverse effect. |
2012-02-10 |
2023-08-12 |
Not clear |
| Alessandra Fanciulli, Roberta Misasi, Dario Campanelli, Francesca R Buttarelli, Francesco R Pontier. Dopaminergic drug-induced modulation of the expression of the dopamine transporter in peripheral blood lymphocytes in Parkinson's disease. Pharmacological reports : PR. vol 63. issue 4. 2012-02-10. PMID:22001994. |
dopaminergic drug-induced modulation of the expression of the dopamine transporter in peripheral blood lymphocytes in parkinson's disease. |
2012-02-10 |
2023-08-12 |
Not clear |